COVID-19 Oral and Injectable Treatments and Monoclonal Antibody Coverage

Updated March 3, 2023

The Food and Drug Administration (FDA) has authorized antiviral medications to treat mild to moderate COVID-19 in people who are more likely to get very sick. Antiviral treatments target specific parts of the virus to stop it from multiplying in the body, helping to prevent severe illness. [i]

The following oral and injectable antiviral treatments currently hold emergency use authorizations (EUA) from the FDA.

COVID-19 Oran and Injectable Treatment Effective Dates		
Medication	Description	MaineCare Effective Date(s)
Paxlovid**-Oral	Nirmatrelvir with Ritonavir	12/22/2021
Veklury*-Injection	Remdesivir	05/01/20
Lagevrio**-Oral	Molnupiravir	12/23/2021
*Veklury received full FDA approval on 10/22/22. All uses previously approved under the EUA were not carried over to the approval. **The initial supply of oral antivirals is purchased by the federal government and distributed free to providers, however, providers will not be reimbursed for ingredient cost.		

Monoclonal antibodies are another form of treatment for COVID-19 for which the FDA has previously issued EUAs. As new strains of the COVID-19 virus appear, the FDA reevaluates these treatments for continued effectiveness, and currently, only tocilizumab remains authorized for use in hospitalized adults and pediatric patients.

The following monoclonal antibodies currently hold, or have held, EUAs from the FDA.

OMS COVID-19 Monoclonal Antibody Treatment Codes & Effective Dates		
Code	**Code Description**	**MaineCare Effective Date(s)**
Genentech EUA Monoclonal Antibody COVID-19 Infusion Treatment		
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	6/24/2021
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	6/24/2021

M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	6/24/2021

Monoclonal Antibodies <u>no longer authorized</u> for use:		
Code	**Code Description**	**MaineCare Effective Date(s)**
Eli Lilly EUA Monoclonal Antibody COVID-19 Infusion Treatment		
Q0239	Injection, bamlanivimab-xxxx, 700 mg	11/10/20-04/16/21*
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	11/10/20-04/16/21*
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	02/09/21-01/24/22**
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	02/09/21-01/24/22**
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	05/06/21-01/24/22**
Q0222	Injection, bebtelovimab, 175 mg	2/11/2022-11/30/22^{+}****
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	2/11/2022-11/30/22^{+}****
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	2/11/2022-11/30/22^{+}****
Regeneron EUA Monoclonal Antibody COVID-19 Infusion Treatment		
Q0240	Injection, casirivimab and imdevimab, 600 mg	7/30/2021-01/24/22**
Q0243	Injection, casirivimab and imdevimab, 2400 mg	11/21/20-01/24/22**
Q0244	Injection, casirivimab and imdevimab, 1200 mg	06/03/21-01/24/22**
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	07/30/21-01/24/22**

M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	07/30/21-01/24/22**
M0243	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	11/21/20-01/24/22**
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	05/06/21-01/24/22**
GlaxoSmithKline EUA Monoclonal Antibody COVID-19 Infusion Treatment		
Q0247	Injection, sotrovimab, 500 mg	05/26/21-02/25/22**
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	05/26/21-02/25/22**
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	05/26/21-02/25/22**
AstraZeneca EUA Monoclonal Antibody COVID-19 Infusion Treatment		
Q0220	Tixagev and cilgav, 300 mg	12/8/2021-01/26/2023***
Q0221	Tixagev and cilgav, 600 mg	02/24/2022-01/26/2023***
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	12/8/2021-01/26/23***

M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	12/8/2021-01/26/23***
*Effective dates ended with the FDA's revocation of the EUA for monoclonal antibody treatment with bamlanivimab alone. **Effective dates ended with the FDA's ending of the EUA for this monoclonal antibody treatment nationally or regionally. ***Effective dates ended with the FDA's ending of the EUA for this monoclonal antibody treatment +Effective 08/15/22 government purchase of bebtelovimab will phase out, please omit SL modifier when billing commercially purchased drugs. ****Effective dates ended with the FDA's ending of the EUA for this monoclonal antibody treatment		

[i] https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html